Dermata Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q2 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Dermata Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2020 to Q3 2024.
  • Dermata Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$3.23M, a 78% decline year-over-year.
  • Dermata Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$11.5M, a 53.1% decline year-over-year.
  • Dermata Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$8.04M, a 16.9% increase from 2022.
  • Dermata Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$9.67M, a 23.1% decline from 2021.
  • Dermata Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$7.86M, a 148% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$11.5M -$3.23M -$1.41M -78% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$10.1M -$2.88M -$1.15M -66.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$8.97M -$3.2M -$926K -40.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$8.04M -$2.22M -$508K -29.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$7.53M -$1.81M +$634K +25.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$8.17M -$1.73M +$998K +36.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$9.17M -$2.28M +$508K +18.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$9.67M -$1.71M +$841K +33% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$10.5M -$2.45M -$734K -42.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$9.78M -$2.73M -$1.4M -105% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$8.38M -$2.79M -$524K -23.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$7.86M -$2.55M Oct 1, 2021 Dec 31, 2021 10-K 2023-02-21
Q3 2021 -$1.71M -$1.17M -217% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$1.33M -$537K -67.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$2.26M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q3 2020 -$540K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$793K Apr 1, 2020 Jun 30, 2020 10-Q 2021-09-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.